NCT06633718View on ClinicalTrials.gov

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

786

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2027

Conditions
Intra-abdominal Infections
Interventions
DRUG

Meropenem and Pralurbactam

3g，q8h，120min infusion

DRUG

Saline

100mL，q8h，60min infusion

DRUG

Ceftazidime-avibactam

2.5g，q8h，120min infusion

DRUG

Metronidazole

0.915g，q8h，60min infusion

Trial Locations (1)

310014

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY